New Phase II data indicate regimen of Truxima (biosimilar rituximab), lenalidomide and acalabrutinib (R2A) may be well tolerated and effective in relapsed/refractory aggressive B-cell lymphoma

Press/Media: Press / Media

Period2020 Jun 15

Media coverage

1

Media coverage

  • TitleNew Phase II data indicate regimen of Truxima (biosimilar rituximab), lenalidomide and acalabrutinib (R2A) may be well tolerated and effective in relapsed/refractory aggressive B-cell lymphoma
    Media name/outletFirstWord Pharma
    Country/TerritoryUnited States
    Date20/6/15
    URLwww.firstwordpharma.com/node/1732861
    PersonsKi woo Kim